The potential role of CD133 as a marker of chemoresistance in nonluminal breast cancer subtypes was also proposed, on the basis of the relative enrichment of CSCs expressing the surface antigen after systemic therapy [29]. This evidence concerns the gene PROM1 and breast cancer.